^
    1d
    Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. (clinicaltrials.gov)
    P1/2, N=75, Active, not recruiting, Massachusetts General Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • ER negative
    |
    Talzenna (talazoparib) • Trodelvy (sacituzumab govitecan-hziy)
    4d
    Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (clinicaltrials.gov)
    P3, N=55, Terminated, Biocon Biologics UK Ltd | N=382 --> 55 | Trial completion date: Nov 2026 --> Dec 2025 | Recruiting --> Terminated; US FDA is streamlining the Biosimilar development. Thus, Biocon decided to terminate the study.
    Enrollment change • Trial completion date • Trial termination
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 overexpression • ER negative
    |
    carboplatin • docetaxel • Perjeta (pertuzumab)
    7d
    Estrogen metabolism-related lifestyle score and risk of postmenopausal breast, endometrial, and ovarian cancers: findings from two large prospective cohort studies. (PubMed, Cancer Prev Res (Phila))
    Lifestyle patterns linked to elevated 2-OH of estrogen were associated with lower risk of postmenopausal breast and endometrial cancers. Our study provides evidence for lifestyle modifications for cancer prevention.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • ER negative
    8d
    Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    9d
    FOXA2 as a SETD1A-Regulated Driver of Tamoxifen Resistance in Breast Cancer. (PubMed, Oncol Res)
    High FOXA2 expression was correlated with poor survival and reduced responsiveness to tamoxifen in patients with ER-positive breast cancer. Our findings identified FOXA2 as a key mediator of tamoxifen resistance regulated by SETD1A and suggested that targeting the SETD1A-FOXA2 axis may offer a novel strategy for overcoming endocrine resistance in breast cancer.
    Journal
    |
    ER (Estrogen receptor) • FOXA2 (Forkhead Box A2) • SETD1A (SET Domain Containing 1A)
    |
    ER positive
    |
    tamoxifen
    11d
    The Long and Winding Road toward Prevention of Estrogen Receptor-Negative and BRCA1-Associated Breast Cancer. (PubMed, Cancer Prev Res (Phila))
    The study by Moyer and colleagues demonstrated that RXR agonists, particularly IRX4204, delay tumor onset in BRCA1-deficient and triple-negative mouse models, suggesting a potential preventive role through immunomodulation...A rational next step may be to carefully design window-of-opportunity trials in BRCA1 carriers undergoing risk-reducing bilateral mastectomy to assess biomarker modulation and tolerability. See related article by Moyer et al., p. 161.
    Journal • BRCA Biomarker
    |
    ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset)
    |
    ER positive • ER negative
    |
    IRX4204
    12d
    Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    carboplatin • albumin-bound paclitaxel • Zolinza (vorinostat)
    13d
    MINA: Microbiome Immunotherapy Neoadjuvant Assessment (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, University College Cork | Trial completion date: Feb 2027 --> Nov 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    PD-L1 IHC 22C3 pharmDx
    15d
    A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Hu Hai
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation • HER-2 negative + HR negative
    |
    Halaven (eribulin mesylate) • Itovebi (inavolisib)
    18d
    TBCRC 041: Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer (clinicaltrials.gov)
    P2, N=96, Completed, Mayo Clinic | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 amplification • HER-2 negative • HER-2 expression • ER negative • HER-2 negative + ER positive
    |
    fulvestrant • alisertib (MLN8237)
    19d
    Estrogen Signaling During Abrupt Involution and Long-Term Metabolic Signature Similar to Estrogen Receptor-Negative Breast Cancer. (PubMed, Int J Mol Sci)
    A subset of AI mice were given tamoxifen for 21 days...Early metabolic phenotypes in AI and GI glands may be related to estrogen signaling. AI long-term transcriptional metabolic effects were similar to breast cancer.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER negative
    |
    tamoxifen
    20d
    IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=540, Recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • IBI-354